Search

What to expect from European Affairs at EHA2024

European Affairs gives a voice to hematology professionals in Europe. The department ensures that the interests of EHA members are duly represented in policy, regulatory and scientific areas and networks.

Read more

Joint Membership

This membership is designed for scientific researchers and physicians from multiple national societies who specialize or are interested in hematology. The main aim is to increase the cooperation in various areas and therefore strengthen hematology at the European level.

Read more

European Affairs Committee

Committee members
Elizabeth Macintyre, France (Chair)
Antonio Almeida, Portugal
Natacha Bolaños, Spain (Patient advocate)
Lorenzo Brunetti, Italy
Raffaella Colombatti, Italy
Julio Delgado, Spain
Isabelle Durand-Zaleski, France (Advisory member)
Tarec El-Galaly, Denmark
Martin Kaiser, Germany
Frank Leebeek, The Netherlands (Advisory member)
Kate Morgan, United Kingdom (Patient advocate)
Marek Mraz, Czech Republic
Kostas Stamatopoulos, Greece
AimThe…

Read more

EHA Diagnosis - Coming soon

Introducing EHA Diagnosis, a educational resource set to support the hematologists with diagnoses and to enhance diagnostic skills. The first beta version of our website is on its way.

Read more

EHA Meetings

Welcome to the overview of upcoming EHA meetings. More information regarding the meetings is available on the individual meeting pages which will be regularly updated.  

Read more

Registration & accommodation

Register here

Individual RegistrationRegistration fee includes:

Access to the scientific and educational sessions of the meeting. Digital meeting materials including the program and abstract book. Networking opportunities during breaks, receptions and dinners.

Read more

Clinical trials

The advance of highly innovative, increasingly personalized therapies in hematology requires novel clinical trial designs and more flexible, adaptive regulatory frameworks and improved data generation to support decision making both during and after clinical studies.

Read more